#Busulfan in modern cancer care

[florenciahealthcare]

BULSUL-FH - Busulphan Injection Manufacturer in India

BULSUL-FH, a Busulfan injection manufactured by Florencia Healthcare, stands as a benchmark in cancer treatment. Known for its role in the treatment of chronic myeloid leukemia (CML) and as a preparatory agent for bone marrow transplants, BULSUL-FH is a testament to Florencia Healthcare's dedication to manufacturing top-notch oncology medications.

This article explores the critical role of Busulfan in modern cancer care, highlighting Florencia Healthcare's expertise in its production. It also answers frequently asked questions to provide a complete understanding of this vital medication.

Understanding BULSUL-FH: What is Bulsul-FH?

Busulfan is an alkylating agent that works by interfering with the DNA and RNA in cancer cells, preventing their growth and replication. BULSUL-FH is Florencia Healthcare's premium formulation of Busulfan injection, designed for maximum efficacy in treating hematologic malignancies.

Key Uses of BULSUL-FH

Chronic Myeloid Leukemia (CML):

Effective in managing this type of blood cancer by slowing the production of abnormal white blood cells.

Conditioning Before Bone Marrow Transplantation (BMT):

Used as part of a conditioning regimen to prepare patients for hematopoietic stem cell transplantation.

Why BULSUL-FH by Florencia Healthcare?

Florencia Healthcare is a trusted name in pharmaceutical manufacturing. Here's why BULSUL-FH is a top choice for healthcare professionals worldwide:

1. WHO-GMP-Certified Manufacturing Facilities

Florencia Healthcare's state-of-the-art manufacturing plants comply with WHO-GMP standards, ensuring that BULSUL-FH meets global quality and safety benchmarks.

2. Rigorous Quality Control

Every batch of BULSUL-FH undergoes stringent quality testing to ensure consistency, purity, and potency.

3. Global Reach

Florencia Healthcare exports its oncology products, including BULSUL-FH, to over 50 countries, making quality cancer care accessible worldwide.

4. Affordability Without Compromise

BULSUL-FH is competitively priced, ensuring that patients receive world-class treatment without financial strain.

The Science Behind BULSUL

Mechanism of Action: Bulsul-FH works by:

DNA Alkylation: Adding alkyl groups to DNA strands, which disrupts cancer cell replication.

Apoptosis Induction: Triggering programmed cell death in malignant cells.

Busulphan’s ability to target rapidly dividing cancer cells makes it particularly effective in hematologic malignancies.

BULSUL-FH: Dosage and Administration

Dosage Guidelines:

The dosage of BULSUL-FH varies depending on the condition being treated:

For CML: Administered orally or intravenously, dosage is determined based on patient weight and disease severity.

For Bone Marrow Transplant Conditioning: Typically administered intravenously over four days in preparation for transplantation.

Administration:

Administered under the supervision of qualified oncologists.

Requires precise monitoring of blood counts and organ function to manage potential side effects.

Note: Always consult a healthcare professional for personalized dosing and administration instructions.

Benefits of BULSUL-FH

Proven Efficacy: Bulsul has decades of clinical success in treating CML and as a conditioning agent in transplants.

Comprehensive Support for BMT: BULSUL-FH plays a critical role in successful bone marrow transplants by effectively suppressing the immune system to reduce rejection risks.

Customizable Treatment Plans: BULSUL-FH is flexible for use in combination therapies, enhancing its therapeutic potential.

Side Effects and Precautions

Common Side Effects:

Nausea and vomiting

Fatigue

Reduced blood cell counts (myelosuppression)

Temporary hair loss

Serious Side Effects:

Liver damage (veno-occlusive disease)

Pulmonary fibrosis

Increased risk of infections due to immunosuppression

Precautions:

Regular monitoring of blood counts, liver, and lung functions is essential during treatment.

Avoid exposure to infections; patients may need to follow specific dietary and hygiene protocols.

Why Florencia Healthcare Stands Out

1. Oncology Expertise

Florencia Healthcare specializes in oncology medications, ensuring every product reflects cutting-edge research and innovation.

2. Patient-Centric Approach

Florencia Healthcare prioritizes accessibility by maintaining an extensive distribution network and offering competitive pricing.

3. Commitment to Innovation

With WHO-GMP-certified facilities, Florencia Healthcare continues to invest in advanced technologies to meet the growing needs of oncology patients.

Conclusion

BULSUL-FH, a premium Busulfan injection from Florencia Healthcare, embodies excellence in cancer care. Its proven efficacy in treating chronic myeloid leukemia and preparing patients for bone marrow transplants highlights its vital role in oncology.

Florencia Healthcare's commitment to innovation, quality, and affordability ensures that BULSUL-FH meets the highest medical standards while being accessible to patients worldwide. By choosing BULSUL-FH, healthcare providers and patients gain a reliable ally in the fight against cancer.

For more information or to purchase BULSUL-FH, visit Florencia Healthcare's official website or reach out to our customer support team. Together, we can make quality cancer care a reality for everyone.

Frequently Asked Questions (FAQs)

1. What is BULSUL-FH used for?

BULSUL-FH is used to treat chronic myeloid leukemia and as a conditioning agent before bone marrow transplantation.

2. How does Bulsul work?

Bulsul disrupts the DNA of cancer cells, preventing them from dividing and growing.

3. Who can benefit from BULSUL-FH?

Patients with CML or those undergoing bone marrow transplants can benefit from BULSUL-FH.

4. Is BULSUL-FH safe for children?

Yes, under strict medical supervision, BULSUL-FH can be used for pediatric patients, particularly in bone marrow transplant cases.

5. What are the side effects of BULSUL-FH?

Common side effects include nausea, fatigue, and reduced blood counts. Serious side effects include liver damage and lung toxicity.

6. Can BULSUL-FH be used in combination with other drugs?

Yes, it is often used in combination with other chemotherapy agents for enhanced effectiveness.

7. How is BULSUL-FH stored?

Store BULSUL-FH in a cool, dry place away from light. Always check the product label for specific storage instructions.

8. Is BULSUL-FH available internationally?

Yes, Florencia Healthcare exports BULSUL-FH to numerous countries worldwide.

9. Why choose Florencia Healthcare for BULSUL-FH?

Florencia Healthcare offers WHO-GMP-certified Busulphan injections that are affordable, high-quality, and globally accessible.

10. How can I purchase BULSUL-FH?

You can contact Florencia Healthcare or their authorized distributors for purchasing BULSUL-FH.

[cancertame3]

What is Chemotherapy?

Chemotherapy (often abbreviated to chemo and sometimes CTX or CTx) is a type of cancer treatment that uses one or more chemotherapeutic agents (anti-cancer drugs) to destroy rapidly growing cells in the body, such as cancer cells which grow and divide faster than other cells in the body. Chemotherapy is primarily used to lower the total number of cancerous cells in the body and shrink tumour size. In the case of advanced stage cancers, chemotherapy may help to relieve pain.

History of Chemotherapy

The use of chemotherapy to treat cancer began at the start of the 20th century. Several attempts were made to narrow down the chemicals that might affect the disease by developing various methods to screen chemicals using transplantable tumours in the rodents. Chemotherapy was first coined as a word in the early 1900s by a German chemist Paul Ehrlich, who defined it as the use of chemicals to treat disease[1].

During World War I, mustard gas was used as a chemical warfare agent. It was discovered that the gas was a potent suppressor of haematopoiesis (blood production). Similarly, nitrogen mustards were studied during World War II after the effects of an accidental spill of sulphur mustards on troops from a bombed ship in Bari Harbour, Italy[2]. This incident led to an observation that both bone marrow and lymph nodes were marked depleted in those who were exposed to mustard gas. It was believed that an agent which could damage the rapidly growing white blood cells might have a similar effect on cancer. The first chemotherapeutic drug developed from this research was Mustine (chlormethine, sold under the brand name of Mustargen). Sidney Farber collaborated with Lederle Laboratories to develop a series of folic acid analogues. These compounds included aminopterin and amethopterin, now known as methotrexate. Farber tested these antifolate compounds in children with leukaemia and in 1948, the results of these tests showed unquestionable remissions[3]. Farber is regarded as the father of modern chemotherapy.

In the mid-1950s, Charles Heidelberger and his colleagues developed a drug that was aimed at non-hematologic cancers[4]. Heidelberger “targeted” a biochemical pathway by attaching a fluorine atom to the 5-position of the uracil pyrimidine base which resulted in the synthesis of fluoropyrimidine 5-fluorouracil (5-FU). This agent was found to have broad-spectrum activity against a range of solid tumours and to this day, remains the cornerstone for the treatment of colorectal cancer. This agent represents the very first example of targeted therapy which has now become a focus in current cancer drug development, although the target, in this case, was a biochemical pathway instead of a molecular pathway.

Methods

There are a number of methods in the administration of chemotherapeutic drugs used today. Chemotherapy may be given with a curative intent or it may aim to prolong life or as palliative care. Induction chemotherapy is considered as the first line of treatment of cancer with a chemotherapeutic drug. It is usually given with curative intent.

Combined modality chemotherapy is the use of drugs along with other cancer treatments like surgery, radiation therapy, ayurvedic treatment (such as Cancertame), homeotherapy treatment etc

Combination chemotherapy involves treating a person with a number of different drugs simultaneously. This is one of the most used methods in chemotherapy as it minimises the chances of resistance developing to any one agent. For the treatment of bladder cancer, for example, a combination of Methotrexate, vincristine, doxorubicin, cisplatin is used

Neoadjuvant chemotherapy is given with an aim to shrink the tumour prior to principal treatment such as radiotherapy or surgery[5]

Adjuvant chemotherapy is given after principal treatment. It is an effective treatment if the cancerous cells have spread to other parts of the body

Types of Chemotherapy

1) Alkylating agents are the oldest group of chemotherapeutics in use today. There are several types of alkylating agents used in chemotherapy treatments such as:

Mustard gas derivatives -  Mechlorethamine, Cyclophosphamide, Chlorambucil, Melphalan, and Ifosfamide

Ethylenimines - Thiotepa and Hexamethylmelamine

Alkyl sulfonates - Busulfan

Hydrazines and Triazines - Altretamine, Procarbazine, Dacarbazine and Temozolomide

Nitrosoureas - Carmustine, Lomustine and Streptozocin.  Nitrosoureas are unique because, unlike most types of chemo treatments, they can cross the blood-brain barrier.  They can be useful in treating brain tumours.

Metal salts - Carboplatin, Cisplatin, and Oxaliplatin

2) Antimetabolites are a group of molecules which impede DNA and RNA synthesis such as:

Folic acid antagonist - Methotrexate

Pyrimidine antagonist - 5-Fluorouracil, Floxuridine, Cytarabine, Capecitabine, and Gemcitabine

Purine antagonist - 6-Mercaptopurine and 6-Thioguanine

Adenosine deaminase inhibitor - Cladribine, Fludarabine, Nelarabine and Pentostatin

3) Topoisomerase Inhibitors are drugs which interfere with the action of topoisomerase enzymes which control the manipulation of the structure of DNA necessary for replication

Topoisomerase I inhibitors - Irinotecan, topotecan

Topoisomerase II inhibitors - Amsacrine, etoposide, etoposide phosphate, teniposide

4) Plant Alkaloids are chemotherapy treatments derived from certain types of plants.

Vinca alkaloids (made from Catharanthus roseus) - Vincristine, Vinblastine and Vinorelbine

Taxanes (made from Taxus) - Paclitaxel and Docetaxel

Podophyllotoxins (derived from may apple plant) - Etoposide and Tenisopide

Camptothecin analogues (derived from camptothecin acuminate) - Irinotecan and Topotecan

Side Effects of Chemotherapy

Chemotherapy can produce adverse side effects that range from mild to severe, depending on the type and extent of the treatment. Some people may experience adverse to a few side effects which vary from person to person and the stage of cancer. Toxicities related to chemotherapy can occur acutely within hours to days, or chronically, after weeks to years[6].

Some common side effects of chemotherapy are:

Nausea and vomiting

Hair loss

Skin changes

Nail changes

Fatigue

Hearing impairment

Infections

Bleeding problems

Anaemia

Loss of appetite

Bowel problems

Cognitive and mental health problems

Luckily, due to advancement in medical research, ayurvedic drugs such as Cancertame when taken along with chemotherapy can minimize such side effects providing for a better integrative treatment for cancer patients.

New Treatment Management Protocols

The practice of utilizing chemotherapy for the treatment of cancer began in the 1940s and still remains a fundamental treatment for various types of cancer. Given the poisonous origin of chemotherapy, patients receiving these treatments experienced some severe side effects which create a demand for new treatment management protocols. Research over the past 30 years has led to the discovery of medications aimed at reducing the side effects of chemotherapy.

Targeted therapies became more popular and are one of the major focus of current cancer drug development. Although the very first use of this method was done back in the 1950s, this therapy aims for the specific targets that are specific to cancer cells and do not occur or are rare in healthy cells

Electrochemotherapy is a combined treatment in which an injection of a chemotherapeutic drug is followed by the application of high-voltage electric pulses to the tumour. This treatment enables the chemotherapeutic drugs, which cannot or hardly go through the membrane of cells, to enter cancer cells

Hyperthermia therapy is a heat treatment of cancer that can be very effective if combined with chemotherapy. The heat can be applied locally to the tumour site, which will dilate blood vessels to the tumour, allowing the more chemotherapeutic medication to enter the tumour. The tumour cell membrane will become more porous which will further allow more of the chemotherapeutic medicine to enter the tumour cell

Other medications such as Cancertame can also help to reduce the side effects of chemotherapy by enhancing the immune system of the body, and also helps to fight the growth of cancer by inducing apoptosis (cell death) and inhibiting tumour angiogenesis.

References

DeVita VT, Chu E (November 2008). "A history of cancer chemotherapy". Cancer Research. 68 (21): 8643–53

Krumbhaar EB, Krumbhaar HD. The blood and bone marrow in yellow gas (mustard gas) poisoning. Changes produced in bone marrow in fatal cases. J Med Res 1919; 40: 497–508

Farber S, Diamond LK, Mercer RD, et al. Temporary remissions in acute leukaemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N Eng. J Med 1948; 238: 787–93

Heidelberger C, Chaudhuari NK, Danenberg P, et al. Fluorinated pyrimidines. A new class of tumor inhibitory compounds. Nature 1957; 179: 663–6

Rachel Airley (2009). Cancer chemotherapy. Wiley-Blackwell

https://www.cancertame.com/in/article.php?title=What%20is%20Chemotherapy?&article_id=VmtkNFUxSXdjM2xYYmxaV1ltMTRjbFpxUmxaUFVUMDk=

https://www.cancertame.com

[newstwitter-blog]

New Post has been published on News Twitter

New Post has been published on http://www.news-twitter.com/2017/01/30/bbc-cancer-drugs-price-rise-costing-nhs-millions-19/

BBC: Cancer drugs price rise 'costing NHS millions'

Image copyright Science Photo Library

Image caption Tamoxifen is used to treat breast cancer

UK prices for generic cancer drugs have risen sharply in the past five years, restricting their use in treating NHS patients, research from the European Cancer Congress has found.

Drugs such as tamoxifen and bulsufan are now 10 times more expensive despite no longer being under patent.

The British Generic Manufacturers Association said trusts often paid much less than the list price.

The Department for Health said it has plans to cut generic drug costs.

The UK researchers said NHS negotiations with drug companies were failing to contain costs, and getting access to cheaper drugs would allow more people to be treated with more modern medicines.

They estimated that the cost of these price rises to the NHS in England was around £380m a year – which only included community-based prescribing, not hospital prescribing.

Rationing

Drugs start off being on-patent, and their high prices allow pharmaceutical companies to profit from their investments in research and development.

After patents have expired and generic versions are sold, the theory is that drug prices should fall close to the cost of production.

However, because of high drug prices, the NHS is often not able to approve some new cancer drugs for use.

New treatments then have to be rationed.

Dr Andrew Hill, senior research fellow in pharmacology and therapeutics at the University of Liverpool, and Melissa Barber from the London School of Hygiene and Tropical Medicine, collected prices on medicines available on the NHS for their presentation at the cancer conference.

They discovered that busulfan, which is used to treat leukaemia, cost 21p per tablet in 2011 and £2.61 in 2016.

Tamoxifen, used to treat breast cancer, cost 10p per tablet in 2011 and £1.21 in 2016.

Of 89 cancer medicines looked at in the analysis, 21 showed price rises from 2011 to 2016 – with 17 of those classified as generic.

Fourteen generic cancer drugs showed price rises of more than 100%.

And compared with prices for the same drugs in India, the UK drugs were roughly 20 times more expensive.

‘Worrying’

Dr Hill said he was surprised to find several companies had consistently raised the prices of cancer treatment.

“We have found that some companies take over the supply of some generic cancer medicines and then raise the price progressively,” he said.

He said this was “worrying”, particularly when the Cancer Drugs Fund is under pressure from high prices.

But Warwick Smith, director-general of the British Generic Manufacturers Association, said the actual prices paid by hospitals were usually much lower than the list prices.

He said the tendered price paid by hospitals for tamoxifen 10mg tablets is £4.85 for a pack of 30, or 16p per tablet.

‘Significant savings’

“Generic competition in the oncology market has produced very significant savings for the NHS and generated access for patients to medicines such as tamoxifen which can be used to reduce the risk of breast cancer and not just to treat it.

“In the case of generic medicines used in hospitals, it is important to distinguish between the actual price paid by trusts and the much higher list prices often quoted.”

The Health Services Medical Supplies (Costs) Bill, currently going through Parliament, is designed to allow the NHS to regulate prices in the future.

As a result of the bill, companies found to be raising prices with no clear justification will be referred to the Competition and Markets Authority, and could face fines.

A Department of Health spokeswoman said: “We will continue to work closely with the pharmaceutical sector to make a success of these new measures, and all the money saved will be invested in the NHS to help provide the highest quality of care for patients.”

Other European countries have taken similar measures.

In Spain and Italy, failure to accept the high prices demanded for some generic treatments has led to warnings from companies that they could stop their supply.

“At a time when cancer patients are living longer and better lives due to effective treatments, this situation is particularly worrying,” Dr Hill said.

This post has been harvested from the source link, and News-Twitter has no responsibility on its content. Source link

[newstwitter-blog]

New Post has been published on News Twitter

New Post has been published on http://www.news-twitter.com/2017/01/30/bbc-cancer-drugs-price-rise-costing-nhs-millions-18/

BBC: Cancer drugs price rise 'costing NHS millions'

Image copyright Science Photo Library

Image caption Tamoxifen is used to treat breast cancer

UK prices for generic cancer drugs have risen sharply in the past five years, restricting their use in treating NHS patients, research from the European Cancer Congress has found.

Drugs such as tamoxifen and bulsufan are now 10 times more expensive despite no longer being under patent.

The British Generic Manufacturers Association said trusts often paid much less than the list price.

The Department for Health said it has plans to cut generic drug costs.

The UK researchers said NHS negotiations with drug companies were failing to contain costs, and getting access to cheaper drugs would allow more people to be treated with more modern medicines.

They estimated that the cost of these price rises to the NHS in England was around £380m a year – which only included community-based prescribing, not hospital prescribing.

Rationing

Drugs start off being on-patent, and their high prices allow pharmaceutical companies to profit from their investments in research and development.

After patents have expired and generic versions are sold, the theory is that drug prices should fall close to the cost of production.

However, because of high drug prices, the NHS is often not able to approve some new cancer drugs for use.

New treatments then have to be rationed.

Dr Andrew Hill, senior research fellow in pharmacology and therapeutics at the University of Liverpool, and Melissa Barber from the London School of Hygiene and Tropical Medicine, collected prices on medicines available on the NHS for their presentation at the cancer conference.

They discovered that busulfan, which is used to treat leukaemia, cost 21p per tablet in 2011 and £2.61 in 2016.

Tamoxifen, used to treat breast cancer, cost 10p per tablet in 2011 and £1.21 in 2016.

Of 89 cancer medicines looked at in the analysis, 21 showed price rises from 2011 to 2016 – with 17 of those classified as generic.

Fourteen generic cancer drugs showed price rises of more than 100%.

And compared with prices for the same drugs in India, the UK drugs were roughly 20 times more expensive.

‘Worrying’

Dr Hill said he was surprised to find several companies had consistently raised the prices of cancer treatment.

“We have found that some companies take over the supply of some generic cancer medicines and then raise the price progressively,” he said.

He said this was “worrying”, particularly when the Cancer Drugs Fund is under pressure from high prices.

But Warwick Smith, director-general of the British Generic Manufacturers Association, said the actual prices paid by hospitals were usually much lower than the list prices.

He said the tendered price paid by hospitals for tamoxifen 10mg tablets is £4.85 for a pack of 30, or 16p per tablet.

‘Significant savings’

“Generic competition in the oncology market has produced very significant savings for the NHS and generated access for patients to medicines such as tamoxifen which can be used to reduce the risk of breast cancer and not just to treat it.

“In the case of generic medicines used in hospitals, it is important to distinguish between the actual price paid by trusts and the much higher list prices often quoted.”

The Health Services Medical Supplies (Costs) Bill, currently going through Parliament, is designed to allow the NHS to regulate prices in the future.

As a result of the bill, companies found to be raising prices with no clear justification will be referred to the Competition and Markets Authority, and could face fines.

A Department of Health spokeswoman said: “We will continue to work closely with the pharmaceutical sector to make a success of these new measures, and all the money saved will be invested in the NHS to help provide the highest quality of care for patients.”

Other European countries have taken similar measures.

In Spain and Italy, failure to accept the high prices demanded for some generic treatments has led to warnings from companies that they could stop their supply.

“At a time when cancer patients are living longer and better lives due to effective treatments, this situation is particularly worrying,” Dr Hill said.

This post has been harvested from the source link, and News-Twitter has no responsibility on its content. Source link

[newstwitter-blog]

New Post has been published on News Twitter

New Post has been published on http://www.news-twitter.com/2017/01/30/bbc-cancer-drugs-price-rise-costing-nhs-millions-17/

BBC: Cancer drugs price rise 'costing NHS millions'

Image copyright Science Photo Library

Image caption Tamoxifen is used to treat breast cancer

UK prices for generic cancer drugs have risen sharply in the past five years, restricting their use in treating NHS patients, research from the European Cancer Congress has found.

Drugs such as tamoxifen and bulsufan are now 10 times more expensive despite no longer being under patent.

The British Generic Manufacturers Association said trusts often paid much less than the list price.

The Department for Health said it has plans to cut generic drug costs.

The UK researchers said NHS negotiations with drug companies were failing to contain costs, and getting access to cheaper drugs would allow more people to be treated with more modern medicines.

They estimated that the cost of these price rises to the NHS in England was around £380m a year – which only included community-based prescribing, not hospital prescribing.

Rationing

Drugs start off being on-patent, and their high prices allow pharmaceutical companies to profit from their investments in research and development.

After patents have expired and generic versions are sold, the theory is that drug prices should fall close to the cost of production.

However, because of high drug prices, the NHS is often not able to approve some new cancer drugs for use.

New treatments then have to be rationed.

Dr Andrew Hill, senior research fellow in pharmacology and therapeutics at the University of Liverpool, and Melissa Barber from the London School of Hygiene and Tropical Medicine, collected prices on medicines available on the NHS for their presentation at the cancer conference.

They discovered that busulfan, which is used to treat leukaemia, cost 21p per tablet in 2011 and £2.61 in 2016.

Tamoxifen, used to treat breast cancer, cost 10p per tablet in 2011 and £1.21 in 2016.

Of 89 cancer medicines looked at in the analysis, 21 showed price rises from 2011 to 2016 – with 17 of those classified as generic.

Fourteen generic cancer drugs showed price rises of more than 100%.

And compared with prices for the same drugs in India, the UK drugs were roughly 20 times more expensive.

‘Worrying’

Dr Hill said he was surprised to find several companies had consistently raised the prices of cancer treatment.

“We have found that some companies take over the supply of some generic cancer medicines and then raise the price progressively,” he said.

He said this was “worrying”, particularly when the Cancer Drugs Fund is under pressure from high prices.

But Warwick Smith, director-general of the British Generic Manufacturers Association, said the actual prices paid by hospitals were usually much lower than the list prices.

He said the tendered price paid by hospitals for tamoxifen 10mg tablets is £4.85 for a pack of 30, or 16p per tablet.

‘Significant savings’

“Generic competition in the oncology market has produced very significant savings for the NHS and generated access for patients to medicines such as tamoxifen which can be used to reduce the risk of breast cancer and not just to treat it.

“In the case of generic medicines used in hospitals, it is important to distinguish between the actual price paid by trusts and the much higher list prices often quoted.”

The Health Services Medical Supplies (Costs) Bill, currently going through Parliament, is designed to allow the NHS to regulate prices in the future.

As a result of the bill, companies found to be raising prices with no clear justification will be referred to the Competition and Markets Authority, and could face fines.

A Department of Health spokeswoman said: “We will continue to work closely with the pharmaceutical sector to make a success of these new measures, and all the money saved will be invested in the NHS to help provide the highest quality of care for patients.”

Other European countries have taken similar measures.

In Spain and Italy, failure to accept the high prices demanded for some generic treatments has led to warnings from companies that they could stop their supply.

“At a time when cancer patients are living longer and better lives due to effective treatments, this situation is particularly worrying,” Dr Hill said.

This post has been harvested from the source link, and News-Twitter has no responsibility on its content. Source link